Video Series

Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, explain the importance of the global Lp(a)HERITAGE study, emphasizing prevalence of elevated Lp(a) among different populations and the evolving approach to assessing Lp(a) levels.

Aaron Gerds, MD, MS, reviews myeloid disorder myelofibrosis and presents diverse symptoms, from blood count variations to spleen enlargement.

Jaime Murillo, MD, explores genetic inheritance patterns of Lp(a) from childhood to adulthood, highlighting stability, factors affecting measurement, and awareness challenges among those in the health care community.

Elizabeth Spencer, MD, discusses how EoE can affect children's activities and social interactions.

Mark Metersky, MD, FCCP, illustrates the pathology of bronchiectasis.

Key opinion leaders highlight the importance of identifying and treating dry eye disease to mitigate long-term economic burdens.

Professionals highlight considerations for the addition of cost-effective, statistically significant therapies to payer formularies.

Key opinion leaders underscore the importance of a multidisciplinary approach that can break down barriers and advance CSCC and BCC therapy.

Experts explore the optimal sequencing of immunotherapy relative to radiation therapy in CSCC and BCC care.

Russell P. Gollard, MD, FACP, highlights the impact of recent advances in hemophilia A treatment on formulary decisions and management approaches.

Panelists provide final considerations surrounding biosimilar usage and considerations for optimal patient care.

Key topics for patient-provider conversations within the biosimilar landscape are highlighted by expert panelists.

Experts address the need for lower costs of treatment, as well as ways payers can support patients with the use of biologics.

Kevin Sheth, MD, discusses the role of computed tomography perfusion amid stroke diagnosis.

A panel of medical experts discuss obstacles hindering the full potential of bispecifics.

Experts explore optimal conditions for effective bispecific therapy in an insightful panel discussion.

Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care.

An overview of the LITESPARK-003 study of belzutifan from ESMO 2023 and the role of HIF2α inhibitors in renal cell carcinoma (RCC).

Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.

Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.

Michael D. Shapiro, DO, reviews and discusses the different guidelines and recommendations on Lp(a) testing.

Elizabeth Yeu, MD, provides a comprehensive overview of Demodex blepharitis stemming from infestations of eyelash follicle mites.

Joseph M. Coney, MD, FACS, underscores the importance of self-reflection to address implicit bias, avoid microaggressions, and foster open communication as key to reducing disparities in health care.

Treatment compliance impacted by oral versus IV therapy is evaluated.

A panel of experts discusses how novel agents are impacting the treatment landscape for patients diagnosed with MDS.

Experts underscore the importance of patient-reported outcomes in tailoring treatments for dry eye disease in patients.

The expert panel provides perspective on current therapeutic gaps and key barriers to care.

Leading experts discuss the evolving role of immunotherapy and neoadjuvant therapies in cSCC and BCC treatment.

Panelists discuss the current prevalence and treatment landscape of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC).